🎧 Part I Podcast free on Apple Podcasts and Spotify.
🎧 Part II Podcast episode.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
The report is a buyer map, with some potholes
Private equity can build the operating infrastructure
Venture capital should solve the missing workflow
The catalyst funding is useful, and conditional
Care delivery needs someone to pay after the pilot
Pharmacy and medtech have their own opportunities
Distribution runs through state procurement
Buying hospitals is a different investment
Underwrite the customer who stays
Abstract
The Rural Health Transformation Program creates a substantial opportunity for investors in healthcare software, services, and delivery infrastructure. Its first obligated funds report shows roughly four billion dollars committed against nearly ten billion dollars in initial state awards, with enormous variation across states. Those commitments reveal specific demand for revenue cycle support, credentialing, cybersecurity, data exchange, remote care, workforce development, and medical equipment. Private equity has a plausible route through established service businesses with rural distribution. Venture capital has a narrower opportunity in repeatable products that solve expensive operational problems, plus conditional funding for early technology development. The central investment challenge is converting temporary public funding into revenue supported by a lasting customer budget. Buying a company because its customers received grants is easy. Establishing what those customers will keep buying takes considerably more work.
The report is a buyer map, with some potholes
A fifty billion dollar healthcare program is going to produce a heroic number of rural strategy decks. The Rural Health Transformation Program will make ten billion dollars available annually across five fiscal years, beginning in fiscal year twenty twenty-six and ending in fiscal year twenty thirty. That is enough money to change purchasing behavior. It isn’t a fifty billion dollar software market, though. Much of the funding supports workforce programs, clinical initiatives, public agencies, and infrastructure. The investable opportunity sits inside particular purchases, contracts, and operating changes. A company needs a product someone is authorized to buy, a route through the purchasing process, and economics that survive after the initial subsidy. The last part tends to get noticeably less space in the deck.
The obligated funds report covers late December twenty twenty-five through the end of July twenty twenty-six. Adding its fifty state award totals produces approximately ten billion dollars. Adding the separately reported state obligation totals produces approximately four billion dollars, or forty percent of those awards. Roughly six billion dollars therefore had not been reported as obligated at that cutoff. Those figures are state-reported obligations, not cash disbursed. The calculation uses the state totals, not the sum of every initiative heading and its underlying line items. It also doesn’t mean six billion dollars remains available today. The information is a July snapshot published in October, and the report explicitly says it is not a complete account of state progress. CMS says the report will be refreshed after the November 30, 2026 quarterly submissions.
The geographic spread is striking. Georgia, Hawaii, and New Hampshire reported obligations equal to their entire initial awards. California reported approximately two hundred nineteen million dollars, nearly ninety-four percent of its award. Florida reported about one million eight hundred thousand dollars against approximately two hundred ten million, less than one percent. New York and West Virginia reported zero. Fifteen states were below ten percent, while eight exceeded ninety percent. Those differences could reflect contracting structures, timing, implementation capacity, or reporting practices. They don’t establish that one state has transformed care and another has accomplished nothing. A state can commit money to an intermediary before that intermediary has selected the companies that will do the work.
There are also actual potholes in the document. Some category subtotals do not reconcile with their listed components, including examples in the Hawaii and Missouri sections. That makes a mechanically generated national technology spending total suspect without reconciliation. The useful approach is to treat individual entries as leads, then obtain the approved scope, recipient information, and relevant procurement documents. An obligation isn’t a vendor payment, and neither one proves recurring revenue. For an investor, the report is unusually useful evidence of purchasing intent. It still needs to be connected to an actual customer.
Private equity can build the operating infrastructure
The most straightforward private equity thesis involves businesses that already help small providers operate. Kansas lists approximately three million six hundred thousand dollars for revenue cycle support and a centralized credentialing organization, plus one million five hundred thousand dollars for a statewide commercial rate analysis. Maryland lists nine hundred thousand dollars for coding, billing, and revenue cycle technical assistance. These are specific buying signals for services with an existing operating rationale. A rural practice doesn’t need another explanation of why cash flow matters. Its billing office may already be held together by two people and an agreement that neither takes vacation at the same time.
A sponsor could acquire a regional revenue cycle or provider administration business with established relationships, then expand the services those customers actually need. Credentialing leads naturally into payer enrollment, roster maintenance, and identifying clinicians who are treating patients before their billing status is ready. Denial management can expose failures in eligibility checks, documentation, or authorization workflows. The financial benefit needs to be measured in incremental collectible revenue and lower operating cost. Faster collections can release working capital without increasing lifetime revenue, while collecting previously abandoned claims can improve both. Treating those outcomes as interchangeable makes the return calculation look better than it is.
Technology implementation offers another route. Mississippi reports forty-seven million five hundred thousand dollars for its rural provider technology grant program. Iowa identifies approximately eleven million seven hundred thousand dollars for implementing its new health information exchange. A regional managed technology provider could supply installation, integration, cybersecurity, and continuing support across multiple facilities. The acquisition target’s value would depend on reusable implementation methods, technician capacity, and customer retention. A collection of unrelated consulting projects won’t become a high-margin software company simply because the sponsor standardizes the invoice template.
The attractive operating model spreads expensive expertise across customers too small to maintain it individually. Security monitoring, identity administration, interface maintenance, and revenue operations all lend themselves to that approach. There is still plenty of execution risk. Rural travel can consume technician capacity, legacy systems can turn fixed-price projects into losses, and understaffed clients can struggle to adopt new workflows. Diligence should examine delivery costs by customer cohort and location, not just consolidated margins. The grant can help a provider afford migration. The ongoing contract has to earn its place in the operating budget.
Venture capital should solve the missing workflow
Venture investors need a different filter. An attractive service business doesn’t automatically support venture returns. The product has to travel across customers without rebuilding the company every time it crosses a state line. Missouri lists approximately four million two hundred thousand dollars for ambient artificial intelligence licenses, deployment, implementation support, and change management. Virginia identifies approximately nine million nine hundred thousand dollars for decision support, documentation, and workflow tools. Those entries establish demand, but also reveal how much sits around the software. Customers need deployment and workflow change alongside access to a model. A startup that overlooks those costs can have impressive contracted revenue and thoroughly unimpressive contribution margins.
The stronger opportunities are narrow enough to measure. A documentation product might reduce the time between a visit and a completed, billable note. A referral product might get a patient into a specialist appointment and return the result to the referring clinician. A credentialing product might identify and resolve missing enrollment information before it causes denied claims. Each has a different buyer and economic justification. Minutes saved don’t automatically become additional appointments, and additional appointments don’t automatically become collected revenue. An underwriting model should follow the chain through to the financial result, including physician review time, correction rates, and the work shifted onto other staff.
Interoperability is another plausible entry point, provided the company tackles the operational mess. Wisconsin lists approximately two million five hundred thousand dollars across closed-loop referral systems for its community and health information exchanges. The difficult work includes patient matching, reconciling local codes, tracking consent, and returning usable information to the right clinical workflow. A referral marked transmitted is not the same thing as a referral completed. An investor should want evidence that the product handles rejected referrals, unavailable appointments, missing records, and patients who never answer the phone. That’s where a supposedly simple workflow acquires enough complexity to support a useful business. Federal guidance places a five percent limit on replacing qualifying existing electronic record systems while exempting upgrades, interfaces, and added functionality from that specific cap. Modular vendors have a concrete opportunity, provided their products actually qualify as enhancements.
The same discipline applies to data products. Clinical records, submitted claims, and remittance information answer different questions. A platform estimating the financial impact of an intervention needs to understand what was delivered, what the payer adjudicated, and what cash ultimately arrived. State funding does not itself grant a vendor unrestricted rights to commercialize patient information. Contractual data rights, permitted uses, provenance, and access after termination belong in product diligence. A defensible company can emerge from reliable integration and workflow performance. A warehouse full of incompletely understood records is mostly an expensive way to postpone the hard questions.
The catalyst funding is useful, and conditional
The Rural Tech Catalyst Fund mechanism deserves separate attention because it can support early development without requiring founders to give up equity. Its limits are specific: a state’s allocation to this type of initiative cannot exceed the lesser of twenty million dollars or ten percent of its award for the budget period, with a separate three million dollar limit on funding to any one company. This is not authority for the state to capitalize a conventional venture fund that generates investment returns. For a venture investor, the opportunity is to finance a qualifying operating company alongside restricted development funding, with each funding source doing a clearly defined job.
Current guidance targets novel, consumer-facing technology for rural chronic disease prevention and management, generally from demonstrated proof of concept through a minimum viable product. It describes applicants founded less than ten years ago with less than fifty million dollars previously raised. Fully commercialized products focused on marketing and sales fall outside that stated development profile. That creates a practical distinction between developing a genuinely new capability and trying to get government funding for an ordinary sales campaign. Virginia’s approximately nine million nine hundred thousand dollar consumer technology innovation entry is worth investigating, but the report alone doesn’t establish a particular company’s eligibility or whether an application window remains open.
The funding can pay for evidence that private investors would otherwise have to finance themselves. A company might test whether a device works reliably under rural connectivity constraints or whether a care intervention produces a meaningful clinical result. The milestone structure still creates working capital needs: the guide allows no more than twenty percent at kickoff, and later payments depend on performance. The guide states that payments are milestone-based and tied to defined technical and outcome milestones, and that budget-period funds must be paid to selected applicants by the end of the subsequent federal fiscal year. For copyrighted work developed with the funding, the government retains royalty-free, nonexclusive rights for federal purposes, including after an acquisition. Patent obligations apply separately. Developers may retain ownership and commercialize their products, subject to applicable requirements. Investors should separate preexisting technology from funded development and understand the resulting rights before assigning value to exclusivity. The useful outcome is better technical evidence and a credible route to paying customers. A successful grant application by itself doesn’t establish either.
Care delivery needs someone to pay after the pilot
The clinical opportunity is substantial, particularly where a regional service can share scarce expertise across several communities. California lists approximately thirty-nine million dollars for hub-and-spoke partnerships and roughly twelve million four hundred thousand dollars for implementation and technical assistance. Utah identifies approximately twenty-four million eight hundred thousand dollars for scalable rural telehealth infrastructure, technology, and services. These commitments could support businesses that make specialty capacity available across dispersed sites. The harder commercial work is deciding how much clinician availability to reserve, how patients enter the service, and who pays when volumes don’t fill the schedule.
Telehealth becomes an operating business once someone has to answer the consult, review the chart, arrange local follow-up, and manage escalation. A psychiatric consultation can improve access while leaving the local practice with additional monitoring responsibilities. A remote specialist can recommend testing that patients cannot obtain nearby. Those handoffs belong in the delivery model and its cost structure. A service with excellent specialist utilization can still fail commercially if each participating clinic needs extensive unreimbursed coordination. Network density matters here, but density means enough appropriate demand within a workable service footprint, not merely a long list of participating locations.
Remote monitoring has the same issue. Virginia lists approximately fourteen million eight hundred thousand dollars covering devices, applications, clinical dashboards, integration, training, and patient engagement support. Device distribution is the beginning of the expense. Someone must enroll patients, troubleshoot equipment, distinguish actionable changes from noise, and act on findings. The sustainable contract could come from a provider, insurer, employer, or organization taking financial responsibility for a population. Those buyers do not share identical incentives. Under volume-based payment, avoiding an admission can reduce hospital revenue while leaving staffing costs largely intact. The agreement needs to allocate the benefit in a way that keeps the necessary providers participating.
The program’s fifteen percent limit on Category B provider payments is relevant, but it isn’t a blanket limit on every dollar reaching a provider. Technology and model implementation can fall under other categories. The prohibition against duplicating existing payment also matters when designing the service. Grant funding should not be casually stacked onto an already reimbursed encounter. For investors, the more durable model has a defined payment pathway and credible outcome measurement. Claims savings should be assessed with adequate follow-up, appropriate comparison groups, and attention to changes in enrollment and patient mix. A decline after enrolling unusually expensive patients can partly reflect regression toward their usual spending. That is a statistical problem, not evidence that the care team has discovered magic.
Pharmacy and medtech have their own opportunities
Pharmacy is an appealing local access point because the operating infrastructure already exists. Missouri lists approximately two million dollars for expanding pharmacy-based services, including testing and treatment, chronic disease management, behavioral health screening, and coordination. Ohio identifies one million one hundred fifty thousand dollars for pharmacy access to electronic medical records. These entries suggest an opportunity to connect pharmacies to clinical workflows that extend beyond dispensing. A useful company could help exchange relevant clinical information, document a service, route follow-up, and submit a claim through the appropriate payment channel.
The pharmacy benefit and medical benefit create very different commercial problems. A paid prescription claim does not establish that a pharmacist’s clinical service will be reimbursed. Scope of practice, payer recognition, enrollment, contracting, and documentation all need to work for the service being offered. Better connectivity also doesn’t repair an unfavorable dispensing contract. A pharmacy acquisition thesis should therefore separate dispensing economics from incremental clinical service economics, including the pharmacist time required. The strongest technology opportunity may sit in the administrative machinery that makes those services deliverable and payable across a network, rather than in owning every participating pharmacy.
Medical equipment produces a different set of opportunities. Texas reports twenty million dollars for advanced medical buses, with local emergency services and fire departments responsible for hosting, staffing, and maintaining them. Pennsylvania’s entries include imaging systems, monitoring equipment, and upgrades to existing facilities. Private equity could find attractive businesses in equipment servicing, deployment, maintenance, and clinical engineering, particularly where a regional footprint improves technician utilization. A grant-financed installation can create continuing service demand, but that demand depends on a working asset with an operating budget. Investors should examine maintenance attachment, parts availability, and who actually funds service after the warranty ends.
For device companies, the grant may overcome the initial purchase barrier while leaving utilization and staffing constraints untouched. A scanner without reliable technician coverage does not become productive because its acquisition cost was subsidized. Capital rules also distinguish existing infrastructure improvements from other equipment uses, and new construction is prohibited. The permitted category depends on the actual project. For pharma and biotech investors, these delivery improvements may eventually support diagnosis, treatment access, or research participation, but drug development and sponsor-funded research need their own commercial rationale. Rural infrastructure funding is not evidence of a new pharmaceutical revenue stream.
Distribution runs through state procurement
The company that understands the buyer can outperform the company with the better demo. The relevant buyer may be a state agency, a hospital association, a university, a regional network, or a provider receiving a subaward. California lists seven million four hundred eighty thousand dollars for third-party grant administration. Alabama identifies approximately five million one hundred fifty thousand dollars for a grant management agreement. These entries show that intermediaries are part of the purchasing structure. They may coordinate implementation or manage downstream funding, but their presence doesn’t establish that they control every vendor decision.
A commercial team should work backward from a specific initiative to the organization with purchasing authority. It needs the approved scope, eligible customer population, procurement route, implementation schedule, and payment conditions. The July obligation percentages can help prioritize investigation, but neither a low nor a high percentage settles whether a sale is possible. A fully obligated state may still have downstream purchasing ahead. A state with few reported obligations may have already advanced substantially since the cutoff. That makes current solicitation and recipient information more valuable than a colorful map ranking states by supposedly available money.
The distinction between a contractor and a subrecipient deserves attention before margins enter the model. A subrecipient carries out part of the funded program; a contractor supplies goods or services through a procurement relationship. Classification follows the substance of the arrangement, not whichever label produces more attractive economics. Federal rules generally prohibit recipients and subrecipients from retaining profit from financial assistance unless expressly authorized. A commercial vendor contract has a different framework. Private ownership alone is not a blanket exclusion from downstream participation, but actual state eligibility and contract terms still govern. A business needs advice on the arrangement it is entering, not a generic conclusion that all federal money works the same way.
For a startup, partnering with an established implementer can reduce the burden of reaching small providers individually. The trade-off is lower margin and less control over the customer relationship. Contract terms should address who renews the software, who supports it, and whether the company can retain the customer if the intermediary’s engagement ends. A large initial order is much less valuable when the startup has no direct route to renewal.
Buying hospitals is a different investment
Buying a struggling rural hospital because a transformation program exists is a much more demanding thesis than acquiring a company that services rural providers. Grants can help fund a defined operational change. They don’t automatically repair unfavorable reimbursement, an unsustainable service mix, a shrinking catchment area, or persistent staffing costs. A hospital can become more technologically capable while remaining economically fragile. The sponsor needs to establish which specific problem is fixable, what the intervention costs, and how the resulting benefit reaches operating cash flow.
Underwrite the customer who stays
The central diligence question is not whether a rural customer can access transformation funding. It is whether the customer will still pay when that funding is no longer the source of the invoice. The CMS report is a useful July snapshot of state-reported obligations, not a forecast of vendor revenue or cash disbursement. The program is now moving through state implementation, procurement, and reporting rather than remaining merely an announced pool of capital.
Investors should trace each opportunity from state award to approved project, from approved project to procurement or subaward, and from that arrangement to the budget that supports renewal. They should distinguish implementation revenue from recurring revenue, grant-funded staffing from permanent staffing, and measurable operating improvement from activity that merely looks busy. Rural transformation can create valuable businesses. The strongest ones will be those that use public funding to establish a service a customer continues to need—and continues to buy.
A plausible acquisition might involve an institution with a viable local role that has accumulated avoidable administrative costs or lost services that could be restored sustainably. The underwriting would still have to examine payer mix, collected rates, workforce availability, referral patterns, and capital needs. Payment methodology matters as much as ownership. A service reduction that appears attractive under one reimbursement structure may have different consequences under another. Adding several fragile facilities to a portfolio doesn’t remove those issues. It can make the financing structure dependent on several simultaneous turnarounds, each with its own local politics and clinical constraints.
Any anticipated grant should be evaluated separately from the acquisition price and ordinary operating funding. The buyer needs to understand whether an award survives a change of control, whether assignment requires consent, what obligations attach to funded equipment, and who bears repayment exposure if conditions are breached. Management service arrangements and affiliated vendors also require scrutiny when public funds are involved. The report itself cannot resolve those questions. Counting an expected award as unrestricted cash available to support acquisition debt is an assumption that needs to be dismantled before signing.
There may be a more practical route through shared services that leaves provider ownership intact. A regional platform can support independent facilities with billing, technology, purchasing, and selected clinical services. That model still needs credible pricing and performance, but it can spread fixed costs without requiring a sponsor to acquire every building and assume every liability. Local governance also has commercial value when the business depends on physician participation and community trust.
Underwrite the customer who stays
The valuation problem is easier to see with an illustrative acquisition. Suppose a business reports ten million dollars in revenue and two million dollars in earnings before interest, taxes, depreciation, and amortization. Four million dollars of that revenue comes from temporary implementation work contributing one million two hundred thousand dollars of those earnings. Without replacement work or further cost reductions, continuing earnings would be eight hundred thousand dollars. Paying ten times the reported two million produces a twenty million dollar purchase price, equivalent to twenty-five times the continuing earnings. The business hasn’t become expensive because the calculation is pessimistic. It has become expensive because different kinds of earnings were priced as if they would last equally long.
Software requires its own version of that analysis. A monthly invoice does not make the underlying demand durable when a temporary grant pays it. Investors should track whether customers renew using their own operating budgets, whether the price changes, and what support costs accompany retention. They should also look through apparent customer diversification. Several dozen provider customers funded by the same state initiative share a material funding exposure. Future state awards and budgets can change, so extending an initial contract value across the entire program is not a substitute for contracted backlog.
Working capital can become the immediate constraint even when the longer-term business is sound. Hiring implementation staff, purchasing equipment, and deploying before payment can consume cash quickly. The financing plan needs to follow actual milestones, acceptance conditions, and payment obligations. Equity or an appropriate credit facility should fund the realistic deployment cycle, including delays. A company can win more contracts than it has the capacity to deliver, and the resulting service problems can damage precisely the relationships that were supposed to produce renewal revenue.
For private equity, the strongest candidates are established operators that can expand an existing customer base while maintaining delivery quality and collecting cash. For venture capital, they are products whose deployment becomes more repeatable, whose economic benefit is measurable, and whose buyers have a reason to keep paying. The program can help fund implementation, clinical validation, and access to customers that were previously difficult to serve. The decisive evidence arrives later, when the subsidy is no longer doing the selling and a customer chooses to renew anyway.
